These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20888974)

  • 1. Cabazitaxel in prostate cancer: stretching a string.
    Dorff TB; Quinn DI
    Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
    [No Abstract]   [Full Text] [Related]  

  • 2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabazitaxel for castration-resistant prostate cancer.
    Shigeta K; Miura Y; Naito Y; Takano T
    Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
    [No Abstract]   [Full Text] [Related]  

  • 5. Cabazitaxel for castration-resistant prostate cancer.
    Froehner M; Wirth MP
    Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
    [No Abstract]   [Full Text] [Related]  

  • 6. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
    Protheroe A
    Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
    Batman E; de Wit R
    Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
    Aktuelle Urol; 2005 Sep; 36(5):385-7. PubMed ID: 16163602
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which drug combination for hormone-refractory prostate cancer?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
    Sleijfer S; Stoter G
    Nat Clin Pract Oncol; 2005 Feb; 2(2):70-1. PubMed ID: 16264874
    [No Abstract]   [Full Text] [Related]  

  • 14. Current chemotherapeutic approaches for androgen-independent prostate cancer.
    Rumohr JA; Chang SS
    Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
    Ferrero JM
    Bull Cancer; 2005 May; 92(5):425-7. PubMed ID: 15932803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in chemotherapy of prostate cancer.
    Heicappell R
    Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
    [No Abstract]   [Full Text] [Related]  

  • 20. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.